Growth Metrics

Fulgent Genetics (FLGT) Accounts Payables (2016 - 2026)

Fulgent Genetics' Accounts Payables history spans 12 years, with the latest figure at $21.1 million for Q1 2026.

  • On a quarterly basis, Accounts Payables rose 15.83% to $21.1 million in Q1 2026 year-over-year; TTM through Mar 2026 was $21.1 million, a 15.83% increase, with the full-year FY2025 number at $18.7 million, up 1.58% from a year prior.
  • Accounts Payables hit $21.1 million in Q1 2026 for Fulgent Genetics, up from $18.7 million in the prior quarter.
  • Over the last five years, Accounts Payables for FLGT hit a ceiling of $37.1 million in Q2 2022 and a floor of $14.5 million in Q3 2022.
  • Historically, Accounts Payables has averaged $20.3 million across 5 years, with a median of $19.6 million in 2024.
  • Biggest five-year swings in Accounts Payables: surged 151.71% in 2022 and later plummeted 44.47% in 2023.
  • Tracing FLGT's Accounts Payables over 5 years: stood at $23.1 million in 2022, then crashed by 33.49% to $15.4 million in 2023, then rose by 19.56% to $18.4 million in 2024, then grew by 1.58% to $18.7 million in 2025, then grew by 13.25% to $21.1 million in 2026.
  • Business Quant data shows Accounts Payables for FLGT at $21.1 million in Q1 2026, $18.7 million in Q4 2025, and $18.1 million in Q3 2025.